

## **Supplemental Material to:**





**Laure-Anne Ligeon, Kevin Moreau, Nicolas Barois,  
Antonino Bongiovanni, Delphine-Armelle Lacorre,  
Elisabeth Werkmeister, Véronique Proux-Gillardeaux,  
Thierry Galli, and Frank Lafont**

**Role of VAMP3 and VAMP7 in the commitment  
of *Yersinia pseudotuberculosis* to LC3-associated pathways  
involving single- or double-membrane vacuoles**

**Autophagy 2014; 10(9)**

**<http://dx.doi.org/10.4161/auto.29411>**

**[www.landesbioscience.com/journals/autophagy/article/29411](http://www.landesbioscience.com/journals/autophagy/article/29411)**

**A****B****C****D**Figure S1 Ligeon *et al.*




Figure S2 Ligeon *et al.*









Figure S3 Ligeon *et al.*









Figure S5 Ligeon *et al.*

1 **Figure S1.** A low proportion of YCVs can reach lysosomes. (A) HeLa cells were infected  
2 with *Y. pseudotuberculosis* for 4 h, treated with LysoTracker<sup>®</sup> Red for 2 h and processed for  
3 CLSM. Bacteria were visualized after staining with DAPI. Scale bars: 5 μm. Magnification:  
4 x5. The percentage of YCVs positive for LysoTracker<sup>®</sup> Red is indicated. In each experiment,  
5 at least 20 cells were quantified in a double-blind analysis. Values are quoted as the mean ±  
6 SEM from at least 3 independent experiments. (B) HeLa cells transiently expressing mRFP-  
7 LC3 were infected with *Y. pseudotuberculosis*. The graph shows the quantification of YCVs  
8 displaying mRFP-LC3 proteins at several time points of infection. Data represent average  
9 percentages of mRFP-LC3-positive YCVs in 3 independent experiments and after the analysis  
10 of at least 20 transfected and infected cells per experiment. (C) HeLa cells transiently  
11 expressing GFP-LC3 were infected with *Y. pseudotuberculosis* and, treated with  
12 LysoTracker<sup>®</sup> Red for 2 h. At 4 h p.i., cells were fixed and processed for CLSM. Bacteria  
13 were visualized after staining with DAPI. Scale bars: 5 μm. Magnification: x5. The  
14 distribution of bacteria is plotted as a function of GFP-LC3 and LysoTracker<sup>®</sup>Red labeling. In  
15 each experiment, at least 20 cells infected with *Y. pseudotuberculosis* were quantified. Data  
16 are displayed as the mean ± SEM from at least 2 independent experiments (D).

17  
18 **Figure S2.** *Y. pseudotuberculosis* uses the LAP pathway to replicate. Intracellular replication  
19 of *Y. pseudotuberculosis* inside HeLa cells treated with *VAMP7* siRNA (A) and *VAMP3*  
20 siRNA (B). Colonies were counted 1 h and 24 h after infection. Data represent the mean ±  
21 SEM of 3 independent experiments. (C) Intracellular replication of *Y. pseudotuberculosis*  
22 inside HeLa cells treated with *ATG5* siRNA. Colonies were counted 1 h and 24 h after  
23 infection. Data represent the mean ± SEM of 3 independent experiments. (D) HeLa cells were  
24 transfected with control siRNA (siCTRL) or siRNA against *ATG5* and then analyzed for  
25 *ATG5* expression by immunoblotting. (E) HeLa cells stably expressing mRFP-GFP-LC3  
26 were infected with *Y. pseudotuberculosis* for 4 h and processed for CLSM. Bacteria were  
27 visualized after staining with DAPI. VAMP7 proteins were detected with anti-VAMP7 rabbit  
28 antibodies and labeled with secondary antibodies coupled to Alexafluor<sup>®</sup>-633. The insert  
29 shows bacteria inside mRFP-GFP-LC3- and VAMP7-positive vacuoles. Scale bars: 5 μm.  
30 Magnification: x4. (F) HeLa cells were infected with *Y. pseudotuberculosis* for 4 h, treated  
31 with LysoTracker<sup>®</sup> Red for 2 h and then processed for CLSM. Bacteria were visualized after  
32 staining with DAPI. LAMP1 was detected with anti-LAMP1 mouse antibodies and labeled  
33 with secondary antibodies coupled to Alexafluor<sup>®</sup>488. VAMP7 proteins were detected with  
34 anti-VAMP7 rabbit antibodies and labeled with secondary antibodies coupled to Alexafluor<sup>®</sup>-

1 633. The insert shows bacteria inside vacuoles that are positive for LAMP1 and VAMP7 but  
2 negative for LysoTracker<sup>®</sup> Red. Scale bars: 5  $\mu$ m. Magnification x4. (G) HeLa cells were  
3 infected with *Y. pseudotuberculosis* for 4 h, treated with LysoTracker<sup>®</sup> Red for 2 h and then  
4 processed for CLSM. Bacteria were visualized after staining with DAPI. CD63 was detected  
5 with anti-CD63 mouse antibodies and labeled with secondary antibodies coupled to  
6 Alexafluor<sup>®</sup>488. VAMP7 proteins were detected with anti-VAMP7 rabbit antibodies and  
7 labeled with secondary antibodies coupled to Alexafluor<sup>®</sup>633 antibodies. The insert shows  
8 bacteria inside vacuoles that are positive for CD63- and VAMP7 but negative for  
9 LysoTracker<sup>®</sup> Red. Scale bars: 5  $\mu$ m. Magnification x5.

10

11 **Figure S3.** VAMP7 is involved in the recruitment of LC3 to YCVs. (A) The complete dataset  
12 for the western blots shown in Figure 5. (B) The LC3-II/TUBULIN ratio for HeLa cells  
13 treated with *VAMP7* siRNA (si*VAMP7*), as a function of cell treatment and infection. Data are  
14 quoted as the mean of at least 3 independent experiments and error bars correspond to the  
15 SEM. (C) Percentage of HeLa cells expressing VAMP7 proteins after treatment with control  
16 or *VAMP7* siRNA. Data are quoted as the mean of at least 2 independent experiments. (D)  
17 The complete dataset for the western blots shown in Figure 6. (E) The LC3-II/TUUBLIN  
18 ratio for BMDMs treated with *VAMP7* siRNA (si*VAMP7*), as a function of cell treatment or  
19 infection. Data are quoted as the mean of at least 3 independent experiments. (F) The  
20 percentage of BMDMs expressing VAMP7 proteins after treatment with control or *VAMP7*  
21 siRNA. Data are quoted as the mean of at least 2 independent experiments.

22

23 **Figure S4.** VAMP3 influences the morphology of autophagosomes. (A) HeLa cells were  
24 transfected with control (siCTRL) or *VAMP3* siRNA (si*VAMP3*), sorted and treated again  
25 with siCTRL or si*VAMP3*, and analyzed for VAMP3 silencing by immunoblotting. Protein  
26 loading was checked against the alpha-tubulin (TUBA) content (panel B). (C) HeLa cells  
27 were transfected with 2 different individual *VAMP4* siRNAs and analyzed by electron  
28 microscopy. The panel shows the quantification of the percentages of YCVs with limiting  
29 single and double membrane. Forty-five cells were analyzed. (D) HeLa cells were transfected  
30 with individual siRNA against *VAMP3* (si*VAMP3* (n<sup>o</sup>1) or si*VAMP3* (n<sup>o</sup>2)) and analyzed for  
31 VAMP3 silencing by immunoblotting. Protein loading was checked against the alpha-tubulin  
32 (TUBA) content (panel E). (F) HeLa cells transfected with pEGFP or pEGFP-VAMP3 were  
33 analyzed for protein expression by immunoblotting using an anti-GFP antibody. (G) HeLa  
34 cells transfected with pEGFP or pEGFP-VAMP3 were analyzed for LC3 by immunoblotting.



1 The cells were treated with rapamycin as indicated and DMSO was used as a solvent control.  
2 Protein loading was checked against the alpha-tubulin (TUBA) content (**H**). (**I**) The LC3-  
3 II/TUBULIN ratio for HeLa transiently expressing EGFP or EGFP-VAMP3, as a function of  
4 cell treatment. (**J**) A panel of 5 TEM images for EGFP-expressing cells treated (or not) with  
5 rapamycin and for EGFP-VAMP3-expressing cells treated with rapamycin (corresponding to  
6 the histogram in **Figure 7I**). The top panels show the profiles of HeLa cells transiently  
7 expressing EGFP; few vacuoles with double membranes were observed. The middle panels  
8 show HeLa cells transfected with EGFP and treated with rapamycin; a greater proportion of  
9 vacuoles with a double membrane were observed (pink arrows). The bottom panels display  
10 double-membrane vacuoles in HeLa cells overexpressing VAMP3 and treated with  
11 rapamycin. The pink arrows show the few observed vacuoles with a double membrane.

12

13 **Figure S5.** VAMP3 does not influence the level of autophagy. (**A**) HeLa cells were  
14 transfected with control siRNA (siCTRL) or siRNA against *VAMP3* (*siVAMP3*) and then  
15 analyzed for LC3 by immunoblotting. The cells were treated with rapamycin and/or BafA1  
16 The LC3-II/TUBULIN ratio as a function of the cell treatment is indicated in panel (**B**). Data  
17 are quoted as the mean of at least 3 independent experiments. (**C**) HeLa cells were transfected  
18 with pEGFP or pEGFP-VAMP3 and then analyzed for LC3 by immunoblotting. The cells  
19 were treated with rapamycin and/or BafA1. The LC3-II/TUUBLIN ratio as a function of the  
20 cell treatment is indicated in panel (**D**). Data are quoted as the mean of at least 2 independent  
21 experiments.

22

23 **Movie S1.** VAMP3 and VAMP7 recruitment to YCVs. HeLa cells transiently expressing  
24 EGFP-VAMP3 (green) and mRFP-VAMP7 (red) were infected with *Y. pseudotuberculosis*,  
25 stained with DAPI (DNA, blue) and directly observed by video microscopy for 3 h 33 min.  
26 The movie shows the migration of EGFP-VAMP3 and mRFP-VAMP7 proteins on a single  
27 YCV. Acquisition times are indicated in the bottom left corner (h:min). Scale bar, 5  $\mu$ m.

28

29 **Movie S2.** VAMP7 and LC3 recruitment to YCVs. HeLa transiently expressing GFP-VAMP7  
30 (green) and mRFP-LC3 (red) were infected with *Y. pseudotuberculosis*, stained with DAPI  
31 and then observed by video microscopy for 1h. The arrows indicate the migration of GFP-  
32 VAMP7 and mRFP-LC3 proteins on a single YCV. Acquisition times are indicated in the  
33 lower left corner (h:min). Scale bar: 5  $\mu$ m.